

Appl. S/N 10/820,121
Amdt dated March 10, 2006
Amendment After Allowance


Page 2 of 6

Amendments to the Claims

This listing of claims will replace all prior version, and listings, of the claims in the application:

Listing of the Claims:

1. (Previously Presented) A pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases, comprising one or more salts of guanidine derivatives corresponding to the formula



wherein

X represents -CH₂-NH-NH- or -CH=N-NH-,

R represents a linear or branched C₁-C₃₀ alkyl, C₃-C₂₀ cycloalkyl, or tricyclodecyl residue, which can be substituted by one or more hydroxyl groups, C₁-C₄ alkoxy groups, C₁-C₄ alkyl groups and/or one or more halogen atoms or one or more amino groups, and

Z represents O-CO-Y, O-S(O)₂-Y, or O-P(O)(OH)-Y, wherein Y represents a linear or branched C₁-C₁₂ alkyl, C₃-C₈ cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C₁-C₄ alkoxy groups, C₁-C₄ alkyl groups and/or one or more halogen atoms or one or more amino groups.

2. (Previously Presented) The preparation according to Claim 1, wherein Z represents O-CO-Y.

3. (Currently Amended) The preparation according to Claim 1, wherein R represents a pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, cyclododecyl, tricyclo[5.2.1.0^{2,6}]-decyl, or bicyclo[2.2.1]-~~heptyl~~ ~~hexyl~~ residue.

Appl. S/N 10/820,121
Amdt dated March 10, 2006
Amendment After Allowance


Page 3 of 6

4. (Previously Presented) The preparation according to Claim 1, wherein R represents a decyl residue.
5. (Previously Presented) The preparation according to Claim 1, wherein Y is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, hydroxyethyl or 2-hydroxy-2,3-dicarboxylic acid propyl.
6. (Cancelled)
7. (Previously Presented) The preparation according to Claim 5, wherein R represents a decyl residue.
8. (Previously Presented) The preparation according to Claim 1, said salt being undecylideneaminoguanidine acetate or undecylideneaminoguanidine lactate.
9. (Previously Presented) The preparation according to Claim 1, said salt being undecylideneaminoguanidine oenanthate or undecylideneaminoguanidine pelargonate.
10. (Previously Presented) The preparation according to Claim 1, said salt being undecylideneaminoguanidine decanoate.
11. (Previously Presented) The preparation according to Claim 1, said salt being undecylideneaminoguanidine hexanoate.
12. (Previously Presented) The preparation according to Claim 1, wherein Z is O-S(O)₂-Y (sulfonic acid group), or O-P(O)(OH)-Y (phosphonic acid group).
13. (Cancelled)
14. (Previously Presented) The preparation according to Claim 1, further comprising a pharmaceutically acceptable additive and/or excipient.
15. (Previously Presented) Method for the preparation of a pharmaceutical preparation for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections,

Appln. S/N 10/820,121
 Amdt dated March 10, 2006
 Amendment After Allowance

Page 4 of 6

or viral diseases, comprising combining one or more salts of guanidine derivatives corresponding to the formula



wherein

X represents -CH₂-NH-NH- or -CH=N-NH-,

R represents a linear or branched C₁-C₃₀ alkyl, C₃-C₂₀ cycloalkyl, or tricyclodecyl residue, which can be substituted by one or more hydroxyl groups, C₁-C₄ alkoxy groups, C₁-C₄ alkyl groups and/or one or more halogen atoms or one or more amino groups, and

Z represents O-CO-Y, O-S(O)₂-Y, or O-P(O)(OH)-Y, wherein Y represents a linear or branched C₁-C₁₂ alkyl, C₃-C₈ cycloalkyl, benzyl, furyl or pyridyl residue, which can be substituted by one or more hydroxyl groups, carboxylic acid groups, C₁-C₄ alkoxy groups, C₁-C₄ alkyl groups and/or one or more halogen atoms or one or more amino groups, with a pharmaceutically acceptable additive and/or excipient to produce an administrable form.

16. (Previously Presented) Method according to Claim 15, comprising: providing approximately equimolar amounts of the corresponding base and acid, and combining the base and acid with the pharmaceutically acceptable additive and/or excipient.

17. (Cancelled)

18. (Previously Presented) Method for the treatment of tumor diseases, autoimmune diseases, cardiovascular diseases, infections, or viral diseases comprising administering to a patient a pharmaceutically effective amount of the pharmaceutical preparation of claim 1.